SMMT 250502 26.50P(SMMT250502P26500) Stock Price Today

US OptionsDetailed Quotes

SMMT250502P26500

Watchlist

0.12
-3.13-96.31%

15min DelayClose May 2 16:00 ET

0.30High0.05Low

Intraday

5D
Daily

News

Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Moomoo News14:31 ET · Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Moomoo News14:31 ET · Ratings
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Moomoo News14:31 ET · Ratings
Express News | Goldman Sachs Maintains Buy on Summit Therapeutics, Raises Price Target to $41
Benzinga13:02 ET
Summit Therapeutics Analyst Ratings
Benzinga13:01 ET · Ratings
Trending Stocks Today | Polyrizon Shoots up 217.71%
Moomoo NewsMay 2 10:55 ET

Comments

sg freeman

Yesterday 12:17

$Summit Therapeutics (SMMT.US)$ insider all converting warrant at cost of 1.x with huge volume, this shit is going to drop tremendously

sg freeman

Yesterday 07:21

$Summit Therapeutics (SMMT.US)$ only 360mil cash left to burn 1.5 year, zero revenue. this should be a penny stock

Adria87

Apr 26 14:59

$Summit Therapeutics (SMMT.US)$

Adria87

Apr 26 12:18

$Summit Therapeutics (SMMT.US)$ overreaction.. it will soon back to the previous price

In His GraceMercy

Apr 26 07:05

Disappointing HR in Interim OS Analysis

$Summit Therapeutics (SMMT.US)$
Akeso, Summit’s partner, released interim overall survival data for ivonescimab, a PD-1/VEGF bispecific antibody, in a Chinese Phase 3 trial (HARMONi-2) comparing it to Merck’s Keytruda for first-line PD-L1-positive non-small cell lung cancer (NSCLC). The hazard ratio for OS was reported as 0.777 (corrected from an initial 0.784), indicating a 22% reduction in the risk of death compared to Keytruda. However, this result was be...